

AUTHORIZED CAR T-CELL THERAPY TREATMENT CENTER IN ATLANTA

**NORTHSIDE HOSPITAL
CANCER INSTITUTE**
IMMUNOTHERAPY PROGRAM

The Blood & Marrow
Transplant Group
O F F G E O R G I A

CALL 404-255-1930 TO SPEAK WITH A PHYSICIAN OR SCHEDULE A CONSULTATION

B-CELL MALIGNANCIES

BREYANZI[®]

Relapsed/Refractory (R/R) Large B-Cell Lymphoma including:

- Diffuse large B-cell lymphoma not otherwise specified, including DLBCL arising from indolent lymphoma
- High-grade B-cell lymphoma
- Primary mediastinal large B-cell lymphoma
- Follicular lymphoma grade 3B
- » Adult patients \geq 18 years
- » Refractory to first-line chemoimmunotherapy or relapse within 12 months of first-line chemoimmunotherapy-OR-
- » Refractory disease to first-line chemoimmunotherapy or relapse after first-line chemoimmunotherapy and are not eligible for hematopoietic stem cell transplantation (HSCT) due to comorbidities or age-OR-
- » After two (2) or more lines of systemic therapy

KYMRIAH[®]

Relapsed/Refractory (R/R) Large B-Cell Lymphoma including:

- Diffuse large B-cell lymphoma not otherwise specified
- DLBCL arising from follicular lymphoma
- High-grade B-cell lymphoma
- Follicular lymphoma
- » Adult patients \geq 18 years
- » After two (2) or more lines of systemic therapy

TECARTUS[®]

Relapsed/Refractory (R/R) Mantle Cell Lymphoma

- » Adult patients \geq 18 years
- » After first line therapy

YESCARTA[®]

Relapsed/Refractory (R/R) Large B-cell Lymphoma

- » Adult patients \geq 18 years
- » Refractory to first-line chemoimmunotherapy or relapse within 12 months of first-line chemoimmunotherapy

Relapsed/Refractory (R/R) Follicular Lymphoma

- » Adult patients \geq 18 years
- » After two (2) or more lines of systemic therapy

Relapsed/Refractory (R/R) Aggressive Large B-Cell Lymphoma

- Diffuse large B-cell lymphoma not otherwise specified
- DLBCL arising from follicular lymphoma
- High-grade B-cell lymphoma
- Primary mediastinal large B-cell lymphoma
- » Adult patients \geq 18 years
- » After two (2) or more lines of systemic therapy

ACUTE LYMPHOBLASTIC LEUKEMIA (ALL)

TECARTUS[®]

Relapsed/Refractory (R/R) B-Cell Precursor Acute Lymphoblastic Leukemia (ALL)

- » Adult patients \geq 18 year

KYMRIAH[®]

B-Cell Precursor Acute Lymphoblastic Leukemia (ALL)

- » Patients \leq 25 years
- » ALL is refractory or in a second or later relapse

MULTIPLE MYELOMA

ABECMA[®]

Relapsed/Refractory (R/R) Multiple Myeloma*:

- After four (4) or more prior lines of therapy including:
 - o An immunomodulatory agent
 - o A proteasome inhibitor
 - o An anti-CD-38 monoclonal antibody

* Newly diagnosed high-risk MM patients (R-ISS III) should be referred soon after initial diagnosis to determine CAR-T eligibility.

CARVYKTI[®]

Relapsed/Refractory (R/R) Multiple Myeloma*:

- After four (4) or more prior lines of therapy including:
 - o An immunomodulatory agent
 - o A proteasome inhibitor
 - o An anti-CD-38 monoclonal antibody

* Newly diagnosed high-risk MM patients (R-ISS III) should be referred soon after initial diagnosis to determine CAR-T eligibility.



CAR T-CELL THERAPY